KRYS vs. NVO
Compare and contrast key facts about Krystal Biotech, Inc. (KRYS) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: KRYS or NVO.
Performance
KRYS vs. NVO - Performance Comparison
Returns By Period
In the year-to-date period, KRYS achieves a 46.94% return, which is significantly higher than NVO's 0.30% return.
KRYS
46.94%
4.05%
11.41%
78.68%
27.42%
N/A
NVO
0.30%
-11.88%
-24.01%
0.48%
32.57%
18.92%
Fundamentals
| KRYS | NVO | |
|---|---|---|
| Market Cap | $5.12B | $472.80B |
| EPS | $1.78 | $2.99 |
| PE Ratio | 99.92 | 34.03 |
| Total Revenue (TTM) | $241.52M | $270.58B |
| Gross Profit (TTM) | $220.04M | $229.07B |
| EBITDA (TTM) | $63.99M | $135.97B |
Key characteristics
| KRYS | NVO | |
|---|---|---|
| Sharpe Ratio | 1.39 | 0.03 |
| Sortino Ratio | 2.78 | 0.27 |
| Omega Ratio | 1.32 | 1.03 |
| Calmar Ratio | 3.49 | 0.03 |
| Martin Ratio | 7.84 | 0.09 |
| Ulcer Index | 10.21% | 10.91% |
| Daily Std Dev | 57.41% | 30.41% |
| Max Drawdown | -53.42% | -71.30% |
| Current Drawdown | -14.68% | -29.88% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between KRYS and NVO is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
KRYS vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
KRYS vs. NVO - Dividend Comparison
KRYS has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 1.41%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KRYS Krystal Biotech, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 1.41% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% | 1.72% |
Drawdowns
KRYS vs. NVO - Drawdown Comparison
The maximum KRYS drawdown since its inception was -53.42%, smaller than the maximum NVO drawdown of -71.30%. Use the drawdown chart below to compare losses from any high point for KRYS and NVO. For additional features, visit the drawdowns tool.
Volatility
KRYS vs. NVO - Volatility Comparison
Krystal Biotech, Inc. (KRYS) has a higher volatility of 13.49% compared to Novo Nordisk A/S (NVO) at 8.75%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
KRYS vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Krystal Biotech, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities